Online Enquiry
Subscribe
Log in / New User
Retrieve Password
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Log In
|
New User Registration
|
Retrieve Password
Log In
News
TheMarket
IndustryNews
RegulatoryNews
GeneralHealth
Legal/IPRNews
Product/R&DNews
API/BulkDrugNews
PeopleintheNews
OtherNews
TopNewsWorldwide
FEATURE ARTICLES
Editorials
Commentaries
ExpertOpinions
Interviews
CaseStudies
CompanyProfiles
Editor'sPicks
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
21 Bridge Street
Metuchen, NJ 08840, USA
Tel/Fax:
+1 801-751-5728
info@pharmachinaonline.com
Affiliated Companies
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
BJ Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel:
+86 10 84476010
info@pharmachinaonline.com
MNC China Business Slows by VBP, Which May Be Expanding to Biologics Soon
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with emphasis on MNC China performance in 2020, threats and opportunities down the road...
(2/27/2021)
Antitrust in China – 2020 Year in Review (3/4/2021)
China's Supreme People's Court Issues Law Inte... (3/4/2021)
FiercePharma: AZ Licenses Junshi's PD-1 in Chi... (3/1/2021)
MNC China Business Slows by VBP, Which May Be ... (2/27/2021)
Biosecurity Law of the P.R.C. - Full Text Unof... (2/25/2021)
PharmaNJ's China NMPA Approved Tracker: Jan 20... (2/25/2021)
PharmaDJ's China Licensing Deals Tracker: Jan ... (2/23/2021)
Review of Chinese Pharma Deals, R&D and Regula... (2/23/2021)
The Race to the Top: Does China Have What It T... (2/22/2021)
How Foreign Companies Can Break Into China's B... (2/22/2021)
NLR: China's Patent Office Releases Draft Meas... (2/9/2021)
SCMP: Phase One Trade Deal Largely A "Failure"... (2/9/2021)
CDE Issues the Requirements for Preclini... (3/8/2021)
Spring Promotion - Pharma China publicat... (3/5/2021)
(Free)
Recent Executive Moves (3/5/2021)
Premier Delivers Government Work Report ... (3/5/2021)
Junshi Initiates Toripalimab Rolling BLA... (3/5/2021)
Abcam Expands in China to Meet Increased... (3/4/2021)
(Free)
Amgen Buys Five Prime to Expand in Asia-... (3/4/2021)
DSM Wins Patent Case against China’s An... (3/4/2021)
China To Set Up 20 More IPR Centers In 2... (3/4/2021)
NHC Holds National Drug Administration T... (3/4/2021)
NHC: China Achieves Phased Success with ... (3/4/2021)
GSK Granted Approval for 2nd Indication ... (3/4/2021)
NMPA Issues the List of Reference Formul... (3/4/2021)
SciClone Launches IPO on the Main Board ... (3/4/2021)
Starton Secures Licensing Deal with Hais... (3/3/2021)
ADC Developer Suzhou Medilink Therapeuti... (3/3/2021)
(Free)
Sun Pharma's NDA for Odomzo (Sonidegib) ... (3/3/2021)
NMPA Revises Packages Inserts of Tramado... (3/3/2021)
Spring Promotion - Pharma China publications
IHS Markit: China Pharma in the Year of the Ox
Anticancer Medicines in China: Trends in Daily Therapy ...
NH Reports on Chinese OTC Eye Care Market in MAT 09/202...
NH Reports Latest Data on Chinese Smoking Control Marke...
SciClone Launches IPO on the Main Board of the Hong Kon...
GSK Granted Approval for 2nd Indication of Lamictal Dis...
Amgen Buys Five Prime to Expand in Asia-Pacific’s Onco...
Abcam Expands in China to Meet Increased Demand of BioP...
Innoforce and dMed Collaborate to Accelerate the Devel...
CDE Issues the Requirements for Preclinical Study Drugs...
NMPA Issues the List of Reference Formulations for GQCE...
NMPA Revises Packages Inserts of Tramadol Injection and...
NMPA Withdraws Approvals of 226 Drug Products Including...
NMPA Solicits Comments on the Draft Measures for Contro...
Premier Delivers Government Work Report at the NPC Sess...
NHC: China Achieves Phased Success with Its Tiered Medi...
NHC Holds National Drug Administration Teleconference, ...
Snapshot of BMI System Financial Performance in 2020
China Further Promotes TCM Development by Strengthening...
China To Set Up 20 More IPR Centers In 2021
DSM Wins Patent Case against China’s Anhui Tiger Vitam...
Wyeth Wins Trademark Infringement and Unfair Competiti...
Boehringer Sues China's Qilu Pharma in the U.S. over Pa...
Bayer's Nexavar Composition Patent Challenged and Inval...
Indian Pharma Firms Go Local Seeking to End Reliance on...
India Probes Alleged API Dumping by Chinese Companies
China Increases Prices of Key Drug Ingredients by Up To...
U.S. Introduces A 'Buy American First' Pharma Executive...
Fitch: No Near-Term Impact on Chinese API Makers as Pha...
Junshi Initiates Toripalimab Rolling BLA Submission for...
Sun Pharma's NDA for Odomzo (Sonidegib) to be Granted P...
AstraZeneca Gains Default Chinese IND Approval for Its ...
China Approves Two More Domestic COVID-19 Vaccines
Harbour BioMed Announces Chinese IND Approval of for Co...
BioAtla and BeiGene Revise Global Deal for Novel Condit...
Pfizer to Absorb Mylan, Creating Global Generic Powerho...
PhRMA Calls for Trade Deals That Force Countries to Pay...
IQVIA: Global Pharma to Grow Slower in the Next Five Ye...
Pfizer and GSK Announce JV to Create a Global Consumer ...
Recent Executive Moves
FBI Accuses Former Jackson Lab Researcher of Failing to...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
U.S. Chamber Releases In-Depth Analysis of U.S.-China E...
Upcoming Event: Plenareno Pharma Middle East Virtual Co...
Live Podcast - VC & Impact Investing in China: Investin...
2020 Fall/Winter Promotion - Pharma China publications
USTR Satisfied with China's Implementatin of Phase 1 US...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
Pharma China on Twitter and Faceboo...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WiCON to Hold Pharma China Annual F...
WiCON Publishes the China Pharmaceu...
WEEKLY e-ALERT(Premium)
WEEKLY e-ALERT(Basic)
GENERAL INFORMATION
TERMS/CONDITIONS OF USE
PRIVACY STATEMENT
JOIN THE MAILING LIST
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit